H.C. WainwrightThe S&P Biotech ETF is up 51% since H.C. Wainwright issued its US$15 target price for AEZS. Moving H.C. Wainwright's target price up 51% with the marekt it could now be C$22.65. As a merger of equals that could translate to C$1.84 for CZO or a C$150 market cap. The net present value of CZO's $40 million immune booster plant alone was $100 million previously and soon PGX could be proven to commercial scale 10X the scale when the net present value of the immune booster plant was discussed. It could also be bringing in revenue and have access to AEZS's $113 million tax loss carryforwards. Then there is a potential CoQ10 partnership in a much larger market than the yeast beta glucan immune booster market. CZO's immune booster may be so unique, however, it may transcend the traditional yeast beta glucan immune booster market into the much, much larger immune booster market more generally.